Drug profile · INN
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted)
FOCLIVIA
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) (FOCLIVIA) is an FDA-listed pharmaceutical active ingredient.
EMA: approved Antiinfectives for systemic use (J07) J07BB02
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) (FOCLIVIA) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted)
Brand FOCLIVIA
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BB02
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted)?
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) (FOCLIVIA) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted)?
FOCLIVIA is a marketed brand name for pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted). Check FDA Drugs@FDA for the current US label holder and prescribing information.